Within 1 month after CD19-CAR-T cell infusion, one CLL patient achieved complete remission (CR), 6 patients (1, 2, and 3 with CLL, DLBCL, and MCL, respectively) had stable disease, 1 MCL patient achieved partial remission, and two CLL patients showed disease progression. This evidence concerns the gene CD19 and mantle cell lymphoma.